Comparison of 99mTc radiolabeled somatostatin antagonist with [68 Ga]Ga-DOTA-TATE in a patient with advanced neuroendocrine tumor-Reference-Cited by-同舟云学术

Comparison of 99mTc radiolabeled somatostatin antagonist with [68 Ga]Ga-DOTA-TATE in a patient with advanced neuroendocrine tumor

Published:2023-07-15 Issue:13 Volume:50 Page:4110-4111
ISSN:1619-7070
Container-title:European Journal of Nuclear Medicine and Molecular Imaging
language:en
Short-container-title:Eur J Nucl Med Mol Imaging

Author:

Opalinska Marta,Lezaic Luka,Decristoforo Clemens,Kolenc Petra,Mikolajczak Renata,Studen Andrej,Simoncic Urban,Virgolini Irene,Trofimiuk-Muldner Malgorzata,Garnuszek Piotr,Rangger Christine,Fani Melpomeni,Glowa Boguslaw,Skorkiewicz Konrad,Hubalewska-Dydejczyk Alicja^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Radiology, Nuclear Medicine and imaging,General Medicine,Radiology, Nuclear Medicine and imaging,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00259-023-06335-9.pdf

Reference4 articles.

1. Fani M, Nicolas GP, Wild D. Somatostatin receptor antagonists for imaging and therapy. J Nucl Med. 2017;58(2):61S-66S. https://doi.org/10.2967/jnumed.116.186783.

2. OECD/NEA. The supply of medical isotopes: an economic diagnosis and possible solutions. OECD Publishing, Paris,. 2019. https://doi.org/10.1787/9b326195-en.

3. Novak D, Janota B, Hörmann AA, Sawicka A, Kroselj M, Hubalewska-Dydejczyk A, Fani M, Mikolajczak R, Kolenc P, Decristoforo C, Garnuszek P. Development of the 99mTc-labelled SST2 antagonist TECANT-1 for a first-in-man multicentre clinical study. Pharmaceutics. 2023;15(3):885. https://doi.org/10.3390/pharmaceutics15030885.

4. Alqahtani FF. SPECT/CT and PET/CT, related radiopharmaceuticals, and areas of application and comparison. Saudi Pharm J. 2023;31(2):312–28. https://doi.org/10.1016/j.jsps.2022.12.013.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Radiolabeled Somatostatin Analogs for Cancer Imaging;Seminars in Nuclear Medicine;2024-08

2. Highlight selection of radiochemistry and radiopharmacy developments by editorial board;EJNMMI Radiopharmacy and Chemistry;2023-10-27